Medtronic Cardiac and Vascular ’s Post

Make sure not to miss out on this excellent webinar!

From May 30 to 31, don’t miss the panel of international experts and attend sessions on AF ablation, ventricular arrythmias and several cases sessions. 👉 Take a look at the synoptic: https://lnkd.in/gks5sBnA The course directors : Jean paul Albenque, Clement Bars, MD, Sonia Busch, K.R. Julian Chun, Deisenhofer Isabel, Tom De Potter, Franck Halimi, Julien Seitz, MD The partners of the Rhythm 2024 congress : Medtronic, Abbott, MicroPort, Biosense Webster, Volta, Boston Scientific, GE HealthCare, Bristol Myers Squibb #Rhythm2024 #RhythmCongress #Arrhythmias #HeartFailure #Rhythmology

Book your time slot during #FRPT2023 to talk with THERYQ team about #FlashRT #Flashradiotherapy #cancerresearch #innovation. Happy to get your insights!

AORTO ILIAC CTO - 2 days of loco-regional fibrinolysis (urokinase) from brachial access - recanalization and aorto iliac IVL bilaterally with Shockwave Medical 8/60 - kissing stent (self-expanding) Epic Boston Scientific 9/60 to save all collaterals (hypogastric, lumbar, IMA) with Cecilia Fenelli, Alessio Beconi

Protocol for the separation of small and large cardiac tissue-derived EVs: Wenjing Liang, Rita H. Najor, and Asa B. Gustafsson at UC San Diego developed a method for isolating small and large extracellular vesicles from both mouse hearts and cardiac tissues obtained from patients. Their protocol involves enzymatic digestion to release EVs from the interstitial space, followed by a process of differential centrifugation and immunoaffinity purification. The EVs obtained through this method are suitable for a range of experiments aimed at understanding their in vivo functions https://lnkd.in/enJPChdZ #extracellularvesicles #exosomes #analyticaldevelopment #protocols #Vesiculab

One of the hottest topics this year in the #TAVI business, the #SMART trial one-year outcomes were published recently. First findings on this RCT were controversial discussed already Be smart and post your experiences and comments here. It is worth it to exchange experiences, opinions and feedback on this important trial in TAVI when it comes to small annuli and clinical outcomes. #patientsfirst Let‘s also take the opportunity to share experiences during this year’s #EuroPCR in #Paris when it comes to clinical outcome in small annuli comparing intra- vs. supra-annular valve design #smarttrial #europcr #patientsfirst #tavi

♤ Our 2nd Xeno Patient Abstract shows "FIRST-EVER OBSERVED CONCURRENT HUMAN AND PIG XENOGRAFT HEART ATRIAL ACTIVITY ON POST CARDIAC XENOTRANSPLANT" ♤ Our 2nd worldwide Xenotransplanted Heart patient Post cardiac XT,12 lead ECG Demonstrated Dual P waves, showing two sources of atrial activity. ♤ Novel pig in human cardiac XT with biatrial anastomosis allowed the first-ever detection of simultaneous human and animal cardiac rhythms. The biatrial anastomosis prevented conduction of the human P wave into the porcine AV node. Post-op factors likely explain the slower porcine than the human atrial rate. https://lnkd.in/eaGPB-vA

What makes a robust iPSC-derived atrial model? If you're looking to develop high-quality, chamber-specific cardiac models for research and toxicity screening, then we can help. Listen to this excerpt of our Senior Scientific Support Manager (and cardiomyocytes expert) Steven Broadbent as he distils over a decade of Axol Bioscience expertise into four steps that can produce a robust iPSC-derived atrial model. This is taken from Steven's masterclass "Building chamber-specific cardiac models with iPSCs" which covers: • Our learnings from over a decade in the cardiac iPSC space • The functional data supporting our atrial and ventricular cardiomyocytes (for use in chamber-specific models) • A look to the future of cardiotoxicity models Click here to access the full webinar recording: https://hubs.la/Q02xc6Q00 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

What makes a robust iPSC-derived atrial model? If you're looking to develop high-quality, chamber-specific cardiac models for research and toxicity screening, then we can help. Listen to this excerpt of our Senior Scientific Support Manager (and cardiomyocytes expert) Steven Broadbent as he distils over a decade of Axol Bioscience expertise into four steps that can produce a robust iPSC-derived atrial model. This is taken from Steven's masterclass "Building chamber-specific cardiac models with iPSCs" which covers: • Our learnings from over a decade in the cardiac iPSC space • The functional data supporting our atrial and ventricular cardiomyocytes (for use in chamber-specific models) • A look to the future of cardiotoxicity models Click here to access the full webinar recording: https://hubs.la/Q02xc6sG0 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

NEW ISSUE 2024 🔉 📌 A State-of-the-Art on Inflammation in Atherosclerosis; 📌 A Mini Focus on Robotics in Coronary Revascularisation; 📌 Ultrasound-guided Transfemoral Access; 📌 The ROTA-CUT Trial; 📌 The ACURATE neo2 Post Market Clinical Follow Up Study; 📌 Evolut PRO vs SAPIEN 3; 📌 QFR to Predict Post-PCI Coronary Events; and more https://ow.ly/OtMi50QmTKE